Correlation between visual acuity and human leukocyte antigen DRB1*04 in patients with Vogt-Koyanagi-Harada disease.
Adrenal Cortex Hormones
/ therapeutic use
Adult
Choroid
/ pathology
Female
HLA-DR Antigens
/ genetics
HLA-DRB1 Chains
Histocompatibility Testing
Humans
Male
Middle Aged
Regression Analysis
Retina
/ pathology
Retrospective Studies
Uveomeningoencephalitic Syndrome
/ drug therapy
Visual Acuity
/ physiology
HLA-DRB1*04
Japanese patients
Vogt-Koyanagi-Harada disease
Journal
BMC ophthalmology
ISSN: 1471-2415
Titre abrégé: BMC Ophthalmol
Pays: England
ID NLM: 100967802
Informations de publication
Date de publication:
07 Nov 2019
07 Nov 2019
Historique:
received:
04
07
2019
accepted:
28
10
2019
entrez:
9
11
2019
pubmed:
9
11
2019
medline:
10
3
2020
Statut:
epublish
Résumé
The common presence of human leukocyte antigen (HLA)-DRB1*04 in Vogt-Koyanagi-Harada (VKH) disease is well known. The aim of this study was to investigate the relationship between visual prognosis and HLA-DRB1*04 alleles during systemic corticosteroid therapy in patients with VKH disease. This retrospective case series included 57 eyes from 29 consecutive patients with treatment-naïve VKH disease who received systemic corticosteroid therapy. Visual acuity, sex, refractive error, central retinal thickness (CRT), central choroidal thickness (CCT), and duration from onset to treatment were measured at initial and final visits. Mean values of parameters were compared with each visit. Genotyping was performed by polymerase chain reaction amplification with sequence-specific primer. Linear regression showed significant differences in logMAR best-corrected visual acuity between the three groups of homozygotes, heterozygotes, and normal subjects at baseline (p < 0.01), at 3 months after treatment (p < 0.01). There was no significant differences at 6 months after treatment (p = 0.257). No significant differences were detected between the three groups in age, sex, refractive error, CRT, CCT, or duration from onset to treatment. Alleles of HLA-DRB1*04 might affect visual prognosis and be related to early response after initiation of treatment in VKH disease.
Sections du résumé
BACKGROUND
BACKGROUND
The common presence of human leukocyte antigen (HLA)-DRB1*04 in Vogt-Koyanagi-Harada (VKH) disease is well known. The aim of this study was to investigate the relationship between visual prognosis and HLA-DRB1*04 alleles during systemic corticosteroid therapy in patients with VKH disease.
METHODS
METHODS
This retrospective case series included 57 eyes from 29 consecutive patients with treatment-naïve VKH disease who received systemic corticosteroid therapy. Visual acuity, sex, refractive error, central retinal thickness (CRT), central choroidal thickness (CCT), and duration from onset to treatment were measured at initial and final visits. Mean values of parameters were compared with each visit. Genotyping was performed by polymerase chain reaction amplification with sequence-specific primer.
RESULTS
RESULTS
Linear regression showed significant differences in logMAR best-corrected visual acuity between the three groups of homozygotes, heterozygotes, and normal subjects at baseline (p < 0.01), at 3 months after treatment (p < 0.01). There was no significant differences at 6 months after treatment (p = 0.257). No significant differences were detected between the three groups in age, sex, refractive error, CRT, CCT, or duration from onset to treatment.
CONCLUSION
CONCLUSIONS
Alleles of HLA-DRB1*04 might affect visual prognosis and be related to early response after initiation of treatment in VKH disease.
Identifiants
pubmed: 31699055
doi: 10.1186/s12886-019-1227-6
pii: 10.1186/s12886-019-1227-6
pmc: PMC6836542
doi:
Substances chimiques
Adrenal Cortex Hormones
0
HLA-DR Antigens
0
HLA-DRB1 Chains
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
214Références
Jpn J Ophthalmol. 2019 Jan;63(1):1-6
pubmed: 30460514
Retina. 2012 Nov-Dec;32(10):2061-9
pubmed: 23095726
Immunogenetics. 1999 Jul;49(7-8):660-5
pubmed: 10369924
Am J Ophthalmol. 2019 Jul 16;:null
pubmed: 31323199
Hum Immunol. 1994 Mar;39(3):169-76
pubmed: 8026985
Hum Immunol. 1999 Dec;60(12):1266-73
pubmed: 10626741
Am J Ophthalmol. 2001 May;131(5):647-52
pubmed: 11336942
Tissue Antigens. 1992 May;39(5):225-35
pubmed: 1357775
Tissue Antigens. 2009 Jan;73(1):1-8
pubmed: 19017300
Rheumatology (Oxford). 2012 May;51(5):794-9
pubmed: 22210660
J Ophthalmic Inflamm Infect. 2014 Jul 22;4:20
pubmed: 25097674
Acta Ophthalmol. 2015 Sep;93(6):e475-80
pubmed: 25565265
Invest Ophthalmol Vis Sci. 1994 Feb;35(2):752-6
pubmed: 7906684
Jpn J Ophthalmol. 1988;32(3):334-43
pubmed: 3230720
Am J Ophthalmol. 2000 Feb;129(2):173-7
pubmed: 10682969
BMC Ophthalmol. 2015 Dec 18;15:181
pubmed: 26677974
Am J Ophthalmol. 1995 Feb;119(2):239-40
pubmed: 7832237
Ophthalmology. 1990 Sep;97(9):1137-42
pubmed: 2234843
Diabetes. 2002 Feb;51(2):545-51
pubmed: 11812768
Sci Rep. 2014 Nov 10;4:6887
pubmed: 25382027
N Engl J Med. 1976 Jul 15;295(3):173
pubmed: 1272341
Autoimmun Rev. 2013 Sep;12(11):1033-8
pubmed: 23567866
Br J Ophthalmol. 2019 Feb;103(2):274-278
pubmed: 29666121
J Clin Epidemiol. 1996 Dec;49(12):1373-9
pubmed: 8970487